Enlivex Therapeutics (NASDAQ:ENLV) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Enlivex Therapeutics (NASDAQ:ENLV) from a sell rating to a hold rating in a research report report published on Saturday.

ENLV has been the subject of several other reports. Zacks Research raised Enlivex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Enlivex Therapeutics in a research report on Friday, June 26th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Enlivex Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $247.50.

Enlivex Therapeutics Stock Down 8.5%

ENLV opened at $1.35 on Friday. The stock’s 50 day moving average price is $4.41 and its two-hundred day moving average price is $10.45. The firm has a market capitalization of $23.61 million, a P/E ratio of -0.16 and a beta of 1.60. Enlivex Therapeutics has a 12-month low of $1.34 and a 12-month high of $27.15.

Hedge Funds Weigh In On Enlivex Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC boosted its position in shares of Enlivex Therapeutics by 99.4% during the 4th quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock valued at $221,000 after acquiring an additional 156,336 shares in the last quarter. Susquehanna International Group LLP increased its stake in Enlivex Therapeutics by 1,428.5% in the second quarter. Susquehanna International Group LLP now owns 157,648 shares of the company’s stock valued at $87,000 after acquiring an additional 147,334 shares during the period. HRT Financial LP raised its position in Enlivex Therapeutics by 719.4% in the fourth quarter. HRT Financial LP now owns 153,990 shares of the company’s stock worth $108,000 after purchasing an additional 135,198 shares in the last quarter. Bank of America Corp DE raised its position in Enlivex Therapeutics by 53.2% in the first quarter. Bank of America Corp DE now owns 130,401 shares of the company’s stock worth $121,000 after purchasing an additional 45,303 shares in the last quarter. Finally, Jane Street Group LLC lifted its stake in Enlivex Therapeutics by 527.4% during the first quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock worth $78,000 after purchasing an additional 67,886 shares during the period. 1.02% of the stock is owned by institutional investors.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.